This session delves into the adoption of artificial intelligence in the cath lab, focusing on clinically useful risk prediction models for coronary and structural interventions. It covers advanced AI-guided intravascular imaging, machine learning applications for adverse event prediction, and critical evaluation of model validation and clinical...

Explore advances in complex endovascular and pulmonary interventions, including the transformation of interventional labs into intelligent learning ecosystems, innovative approaches to peripheral and coronary CTOs, and novel therapies such as extravascular renal denervation and fixation catheters for acute pulmonary embolism.

This session presents case-based strategies for mitral paravalvular leak closure, highlighting complex percutaneous approaches including multivalvular failure management, apical access techniques, and transatrial direct surgical valve-in-MAC procedures. It features challenging clinical scenarios demonstrating innovative solutions for hemolytic leaks and complex paravalvular defects.

This session addresses the management of rare and complex clinical scenarios encountered in the catheterization laboratory. Cases include dyspnea in coronary artery bypass graft patients, aortocoronary dissection management, complications during coronary sinus reducer implantation, coronary artery aneurysms related to IgG4 vasculitis, ibuprofen-induced Kounis syndrome, and challenging...

Martin Bergmann reviews the evolving evidence for LAAC, examining how recent landmark trials such as OPTION, CLOSURE‑AF and CHAMPION‑AF are reshaping patient selection and expanding the role of LAAC across a broader spectrum of patients with atrial fibrillation.

In this article, Bruno Scheller explores advances in local drug delivery, from drug-coated balloons to novel antiproliferative agents. These innovations aim to reduce restenosis, minimize permanent implants, and pave the way for patient-specific coronary artery disease treatments.

Fernando Alfonso and Javier Cuesta discuss the growing role of drug-coated balloons as an alternative to stents in percutaneous coronary interventions. Highlighting advantages like reduced in-stent restenosis, they emphasize the need for robust clinical studies to refine DCB use.